{"groups":[{"description":"Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) until disease progression.","id":"FG000","title":"M3258 10 mg QD"},{"description":"Participants received M3258 at a dose of 10 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"FG001","title":"M3258 10 mg Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"FG002","title":"M3258 20 mg Twice Per Week"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"comment":"1 participant received actual dose of 10 mg in Cycle 1 Day 1 instead of planned 20 mg and was summarized with the 10 mg dose level for PK analysis set.","groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"}],"type":"Pharmacokinetic (PK) Analysis Set"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"comment":"1 participant received actual dose of 10 mg in Cycle 1 Day 1 instead of planned 20 mg and was summarized with the 10 mg dose level for Pd analysis set.","groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"}],"type":"Pharmacodynamics (Pd) Analysis Set"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This study was planned to be conducted in 2 parts; Part A: Dose escalation part and Part B: Dose expansion part. However, because of early discontinuation, only Part A was conducted; due to lack of participant enrollment before Part A reached its primary objective and before Part B was started.","recruitmentDetails":"First participant signed informed consent: 26 September 2019, Last participant last visit: 01 April 2021."}